Corrected diffusion capacity of carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary continuous oxygen
Patients requiring supplementary continuous oxygen and/or diffusion capacity of the lung of carbon monoxide (DLCO) < 40%
Corrected diffusion capacity of the lungs for carbon monoxide (DLCO) < 50% of predicted, forced expiratory volume in one second (FEV1) < 50% of predicted, and/or receiving supplementary continuous oxygen; the FHCRC principal investigator (PI) of the study must approve of enrollment of all patients with pulmonary nodules
Diffusion capacity of the lung for carbon monoxide (DLCO) < 40% (corrected), total lung capacity (TLC) < 40%, forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary continuous oxygen
Subject has known pulmonary disease with diffusion capacity of lung for carbon monoxide (DLCO) ? 65%, forced expiratory volume in the first second (FEV1) ? 65%, dyspnea at rest or requiring oxygen or any pleural neoplasm (Transient use of supplemental oxygen is allowed.)
Diffusing capacity of the lung for carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary continuous oxygen
Diffusing capacity of the lung for carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in 1 second (FEV1) < 40% and/or requiring continuous supplementary oxygen, or severe deficits in pulmonary function testing as defined by pulmonary consultant service; and the FHCRC principal investigator (PI) of the study must approve of enrollment of all patients with pulmonary nodules
Pulmonary dysfunction as measured by a corrected diffusing capacity of the lung for carbon monoxide (DLCO) < 50% of predicted total lung capacity (TLC) < 30%, forced expiratory volume in 1 second (FEV1) < 30% and/or receiving supplementary continuous oxygen; the FHCRC principal investigator (PI) of the study must approve enrollment of all patients with pulmonary nodules
Corrected diffusion capacity of the lung for carbon monoxide (DLCO) < 40% of predicted, total lung capacity (TLC) < 30% of predicted, forced expiratory volume in one second (FEV1) < 30% of predicted, or receiving continuous supplementary oxygen
Patients with poor lung function (forced expiratory volume in one second [FEV1]% < 50% or diffusion capacity of carbon monoxide [DLCO] < 50% predicted or home oxygen requirement) and lung lesions undergoing non-anatomic lung resection (i.e. wedge resection) OR
Patients must have a forced expiratory volume in one second (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO) > 50% predicted
Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for hemoglobin [Hb]) >= 50% adjusted
Forced expiratory volume in 1 second (FEV-1) or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) >= 50% predicted; timeline: within 4 weeks prior to enrollment
Pulmonary function tests within 6 months of study enrollment must have forced expiratory volume in 1 second (FEV1) >= 1.2 L and diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted; patients with FEV1 of < 1.2 L but a predicted value of >= 40% may be eligible after review of the case by the study radiation primary investigator (PI) or his designee
Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? 40% (adjusted for hemoglobin) and forced expiratory volume in one second (FEV1) ? 50%
Participant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ? 50% predicted and/or forced expiratory volume in 1 second (FEV1) ? 50% predicted.
Forced expiratory volume in one second (FEV1) or diffusing capacity of the lung for carbon monoxide (DLCO) < 40% or need for use of supplemental oxygen
Forced expiratory volume in one second (FEV1) of < 50% predicted or carbon monoxide diffusing capacity (DLCO) (corrected) < 40% (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing)
Carbon monoxide diffusing capacity (DLCO) and forced expiratory volume in 1 second (FEV1) > 50% predicted
Pulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal value
Diffusion capacity of the lung for carbon monoxide/alveolar volume ratio (DLCO/VA) and forced expiratory volume in 1 second (FEV1) >= 50% of predicted on pulmonary function tests (subjects must have pulmonary function tests performed to be eligible)
Known forced expiratory volume in 1 second (FEV1) or corrected carbon monoxide diffusing capability (cDLCO) < 50% of predicted
No significant obstructive airways disease (forced expiratory volume in 1 second [FEV1] must be >= 50%) and must have acceptable diffusion capacity (corrected carbon monoxide diffusing capability [DLCO] > 50% of predicted)
Carbon monoxide diffusing capability test (DLCO) (adjusted for hemoglobin) >= 50% of predicted and forced expiratory volume in 1 second (FEV-1) >= 50%
Pulmonary function test including diffusion capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV1) and DLCO should be greater than 50% of predicted normal value
Forced expiratory volume in 1 second (FEV1) and carbon monoxide diffusing capability test (DLCO) >= 40% predicted (or per institutional standard)
Have adequate pulmonary function to tolerate surgery; patients must have a diffusing lung capacity for carbon monoxide (DLCO) > 35% of predicted post operative forced expiratory volume in 1 second (FEV1) (ppoFEV1) > 35% of predicted
Adequate pulmonary function defined as NO severe or symptomatic restrictive or obstructive lung disease, and formal pulmonary function testing showing an forced expiratory volume in 1 second (FEV1) >= 50% of predicted and a diffusion capacity of the lungs for carbon monoxide (DLCO) >= 40% of predicted, corrected for hemoglobin
DLCO (diffusing capacity of the lung for carbon monoxide) >= 45% of predicted corrected for hemoglobin, FEV-1 (forced expiratory volume at 1 second) >= 50% of predicted
Diffusing capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1) > 60% predicted
Forced expiratory volume in one second (FEV1) > 65% of predicted measured, or diffusing capacity of the lung for carbon monoxide (DLCO) > 50% of predicted measured
Within 90 days of registration: pulmonary function tests (PFTs) including forced expiratory volume in one second (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO)
Carbon monoxide diffusing capability test (DLCO) or forced expiratory volume in 1 second (FEV1) < 65% predicted
Diffusion capacity of carbon monoxide (DLCO) or forced expiratory volume in one second (FEV1) > 45% predicted
Diffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in 1 second (FEV1) > 45% predicted
Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted normal value
Pulmonary (forced expiratory volume in 1 second [FEV1] > 60% predicted and corrected diffusion capacity of the lung for carbon monoxide [DLCOcor] > 60% predicted)
Forced expiratory volume in one second (FEV1) > 65% of predicted measured, or diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted measured
Patient has diffusion capacity of the lung for carbon monoxide (DLCO) < 50% predicted or forced expiratory volume in 1 second (FEV1) < 50% of predicted, if applicable
Patients must have no significant obstructive airways disease (forced expiratory volume in one second [FEV1] must be >= 50% of predicted) and must have acceptable diffusion capacity (corrected diffusion capacity of carbon monoxide [DLCO] > 50% of predicted)
Pulmonary-forced expiratory volume in 1 second (FEV1) or carbon monoxide diffusing capability (DLco) < 40% or need for use of supplemental oxygen
Within 30 days of registration: Corrected carbon monoxide diffusing capability (DLCO) and forced expiratory volume in 1 second (FEV1), >= 60% predicted
Diffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in 1 second (FEV1) > 45% predicted
Pulmonary function tests, including diffusion capacity of carbon monoxide (DLCO), within 6 weeks prior to registration; patients must have forced expiratory volume in 1 second (FEV1) >= 1.2 Liter or >= 50% predicted without bronchodilator
Lung diffusion capacity for carbon monoxide (DLCO) > 50%, or forced expiratory volume at 1.0 seconds (FEV1.0) > 65% of predicted on pulmonary function testing (PFT) obtained within 28 days of study enrollment
Other serious medical conditions considered to represent contraindications to bone marrow transplant (BMT) (e.g. abnormally decreased cardiac ejection fraction, diffusion capacity of the lung for carbon monoxide (DLCO) < 50% predicted, forced expiratory volume in one second (FEV1) < 70% predicted, acquired immune deficiency syndrome [AIDS], etc.)
Patients must have no significant obstructive airways disease (forced expiratory volume in 1 second [FEV1] must be >= 50%) and must have acceptable diffusion capacity (corrected diffusion capacity of the lung for carbon monoxide [DLCO] > 50% of predicted)
Patients with a diffusing capacity of the lung for carbon monoxide (DLCO) < 55% of normal or a forced expiratory volume in one second (FEV1) < 60% of normal, based on either NIH or United States (USA) normal ranges
Forced Expiratory Volume at one second (FEV1) > 1.2 liters; Diffusion Capacity of Lung for Carbon Monoxide (DLCO) ? 50% predicted
Forced expiratory volume in one second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) >= 50% predicted
Forced expiratory volume in one second (FEV1) >= 50% or diffusing capacity of the lungs for carbon monoxide (DLCO) (hemoglobin [Hb]) >= 40% of predicted, unless pulmonary dysfunction is deemed to be due to chronic GVHD
Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin > 40%; and forced expiratory volume in one second (FEV1) > 50%
Diffusing capacity of the lung for carbon monoxide (DLCO)/alveolar volume (VA) and forced expiratory volume in 1 second (FEV-1.0) >= 60% of predicted on pulmonary function tests
Must have adequate lung function defined within 150 days prior to registration as: (1) forced expiratory volume in 1 second (FEV1) > 30% of predicted or > 800 ml, (2) diffusing capacity of the lung for carbon monoxide (DLCO) > 30 % predicted
Forced expiratory volume in 1 second (FEV1) > 60% and diffusion capacity of the lung for carbon monoxide (DLCO) > 50% of predicted lower limit
Forced expiratory volume in one second (FEV1) of >= 1 liter and diffusion capacity of carbon monoxide (DLCO) >= 40% of predicted
Forced expiratory volume in 1 second (FEV1) > 50% of predicted and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted
Diffusion capacity of the lung for carbon monoxide (DLCO)/DLCO corrected for alveolar volume (VA) and forced expiratory volume in one second (FEV-1.0) > 50% of predicted on pulmonary function tests
Forced expiratory volume in 1 second (FEV1) >= 50% or diffusion capacity of the lung for carbon monoxide (DLCO) (hemoglobin [Hb]) >= 40% of predicted, unless pulmonary dysfunction is deemed to be due to chronic GVHD
Pulmonary function test including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV1) and DLCO should be greater than 50% of predicted normal value
Carbon monoxide diffusing capability test (DLCO) >= 50% (adjusted for hemoglobin) and forced expiratory volume in 1 second (FEV1) >= 50%
Pulmonary function: carbon monoxide diffusing capability test (DLCO) >= 40% (adjusted for hemoglobin) and forced expiratory volume in 1 second (FEV1) >= 50%
Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? 40% (adjusted for hemoglobin) and forced expiratory volume in one second (FEV1) ? 50%
Document forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years).\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in one second (FEV1) =< 50% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (approximately 20 packs/year within the past 2 years).\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume-one second (FEV1) less than or equal to 50% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (approximately 20 packs/year within the past two years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) less than or equal to 50% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) =< 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (approximately 20 packs/year within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Pulmonary function testing in patients with:\r\n* A prolonged history of cigarette smoking (20 pk/yr of smoking within the past two years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs (pk)/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) =< 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (>= 20 pack-year smoking history with cessation within the past two years)\r\n* Symptoms of respiratory dysfunction
Documented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs [pk]/year of smoking within the past 2 years).\r\n* Symptoms of respiratory dysfunction
Forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from Hodgkin lymphoma (HL)
Patients with Adequate Physical Function as Measured by: a. Cardiac: Left ventricular ejection fraction at rest must be greater than or equal to 40%, or shortening fraction less than 25%; b. Hepatic: Bilirubin less than or equal to 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and Alkaline Phosphatase less than 5 x upper limit of normal; c. Renal: Serum creatinine within normal range, or if serum creatinine outside normal range, then renal function (measured or estimated creatinine clearance or GFR)greater than 40 mL/min/1.73m^; d. Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) greater than 50% predicted;
TREATMENT INCLUSION: Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) ? 50% of expected corrected for hemoglobin
Forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) >= 50% predicted
Pulmonary function tests (spirometry) demonstrating forced expiratory value (FEV) 1 greater than 65% predicted or forced vital capacity (FVC) greater than 65% of predicted.
Subjects must have had recent pulmonary function test (PFT) measured for at least 3 months prior to study enrollment that show:\r\n* A decrease in % forced vital capacity (FVC) and/or % forced expiratory volume in 1 second (FEV1) ? 20% at screening compared with pre-transplant baseline\r\n* Lack of bronchodilator response on PFT testing < 12% change and < 200 ml change in FEV1 and/or FVC
If pulmonary function tests (PFTs) are performed, the forced expiratory volume 1 (FEV1)/forced vital capacity (FVC) must be greater than 60%
Diffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) > 50% predicted
Patients with moderate to severe lung disease including: \r\n* Patients requiring oxygen (O2) supplementation\r\n* Patients unable to walk 50 feet without stopping to rest\r\n** Obstructive lung disease as defined by pre-transplant forced expiratory volume in one second (FEV1) =< 60% of predicted\r\n** Restrictive lung disease as defined by pre-transplant forced vital capacity (FVC) < 60% of predicted
Adequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion lung capacity (DLCO) (corrected for hemoglobin [Hgb]) >= 50% of the predicted value
Patients with pulmonary function test abnormalities as evidenced by a forced expiratory volume in 1 second to forced vital capacity ratio measurement (FEV1/FVC) < 70% of predicted for normality will be excluded
Carbon monoxide diffusing capability (DLCO) (corrected for hemoglobin), forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) > 50% predicted
Diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume 1 (FEV1), forced vital capacity (FVC) > 40% predicted, and absence of oxygen (O2) requirements; for children that are not able to cooperate with pulmonary function tests (PFTs), a pulse oximetry with exercise should be attempted; if nether test can be obtained it should be clearly stated in the provider’s note
Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume; children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >= 92% on room air
For patients >= 8 years of age (or otherwise able to complete pulmonary function testing per established American Thoracic Society standards), diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected/adjusted for hemoglobin) > 40% and forced expiratory volume in one second (FEV1) > 50% predicted (without administration of bronchodilator) and forced volume vital capacity (FVC) > 50% predicted
Adjusted diffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), and forced vital capacity (FVC) >= 50% of predicted value (corrected for hemoglobin)
Diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) >= 40% predicted, and absence of oxygen (O2) requirements; for children that are not able to cooperate with pulmonary function tests (PFTs), a pulse oximetry with exercise should be attempted; if neither test can be obtained it should be clearly stated in the physician’s note
Patients who have a significant history of pulmonary disease that necessitates the use of supplemental oxygen, is associated with dyspnea on walking one block or less, or requires inhaler therapy more than once per week will be required to undergo pulmonary function testing within 6 months of screening and will be excluded if forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), or diffusing capacity of the lungs for carbon monoxide (DLCO) is less than 65% of predicted
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and corrected diffusing capacity of the lungs for carbon monoxide (DLCO) >= 40%
Adequate pulmonary function as defined by forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted by pulmonary function testing
Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume
Pulmonary function tests (forced expiratory volume in 1 second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted) within 1 month of lymphodepletion
Diffusing lung capacity for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) > 50%; DLCO should be corrected for hemoglobin
Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) should be 50% or above of expected
Pulmonary function tests (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC], carbon monoxide diffusing capability [DLCO] >= 40%
Pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) at least 45% of expected corrected for hemoglobin; children unable to perform pulmonary functions must have an oxygen saturation greater than 92% at room air
The following pulmonary function tests (PFT) values in baseline:\r\n* Forced expiratory volume in one second (FEV1) > 80% predicted\r\n* FEV1/forced vital capacity (FVC) > 80%\r\n* Residual volume (RV)/total lung capacity (TLV) >= 80%
Adequate pulmonary reserve defined as adequate airflow defined by a measured forced expiratory volume (FEV1) not less than 50% of the predicted value and adequate pulmonary reserve as evidenced by a FEV1/forced vital capacity (FVC) ratio of 65% or greater
Pulmonary function tests (forced expiratory volume in one second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted) within 6 months of lymphodepletion (Turnstile II)
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) > 50% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then oxygen (O2) saturation > 92% on room air
Adequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin; exceptions may be allowed for patients with pulmonary involvement after discussing with Principal Investigator (PI)
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), diffusion capacity of carbon monoxide (DLCO) (diffusion capacity) >= 40% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then oxygen (O2) saturation > 92% on room air
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) < 40% predicted
Pulmonary function tests (forced expiratory volume in one second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted) within 6 months of lymphodepletion (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 65% of predicted (patients >= 40 years old)
Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) > 50% of predicted value (corrected for hemoglobin) within 3 months of registration.
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCOc) >= 50% of predicted).
Normal lung function; patients who have extensive pulmonary metastases or any chronic pulmonary disease history must have pulmonary function testing demonstrating forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) > 65% of predicted values
Diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) > 50%\r\n* DLCO should be corrected for hemoglobin
Pulmonary function tests (forced expiratory volume in one second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted are required) within 6 months of lymphodepletion in those who have a history of pulmonary disease that necessitates the use of supplemental oxygen, or is associated with dyspnea on walking one block or less, or requires inhaler therapy more than once per week
Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) >= 50% of predicted (corrected for hemoglobin)
Adequate lung function; forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) ? 45% of predicted value as measured by spirometry; and oxygen saturation ? 90% on room air
Pulmonary function tests (PFTs) are required of all patients within 4 months prior to lymphodepletion; forced expiratory volume (FEV)1 and forced vital capacity (FVC) must be >= 65% predicted and diffusion lung capacity for carbon monoxide (DLCO) must be >= 50% predicted
Diffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) >= 50% of predicted value (corrected for hemoglobin) within 3 months of registration
Adequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin
Pulmonary: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume (FEV1), forced vital capacity (FVC) ? 50% predicted by pulmonary function tests (PFTs)
Forced expiratory volume in one second (FEV1) AND forced vital capacity (FVC) > 50% predicted
Participants must have adequate pulmonary function studies (PFTs), >= 50% of predicted on mechanical aspects (forced expiratory volume in 1 second [FEV^1], forced vital capacity [FVC]) and diffusion capacity (diffusion capacity of the lung for carbon monoxide [DLCO]) >= 50% of predicted (adjusted for hemoglobin); if the participant is unable to complete pulmonary function tests (PFTs) due to disease-related pain or other circumstances that make it difficult to reliably perform PFTs, documentation of pulmonary function adequate for transplant will occur via a CT scan without evidence of major pulmonary disease, and arterial blood gas results
Forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and forced vital capacity all > 50% predicted value; Note: pulmonary function testing is not required for children < 8 years old, or for any child who is developmentally unable to comply with pulmonary function testing
Spirometry (forced expiratory volume in one second [FEV1] and forced vital capacity [FVC]) & corrected diffusing capacity of lungs for carbon monoxide (DLCO) >= 50% predicted; in small children use history and physical computed tomography (CT) scan to determine pulmonary status
Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume; children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >= 92% on room air
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) >= 60% and corrected diffusion capacity of the lung for carbon monoxide (DLCO) >= 60%
Hepatic: i. Total Bilirubin < 2.0 mg/dL (except for isolated hyperbilirubinemia attributed to Gilbert syndrome or antiretroviral therapy as specified in Appendix E) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5x the upper limit of normal. ii. Concomitant Hepatitis: Patients with chronic hepatitis B or C may be enrolled on the trial providing the above bilirubin and transaminase criteria are met. In addition, there must be no clinical or pathologic evidence of irreversible chronic liver disease, and there must be no active viral replication as evidenced by an undetectable hepatitis viral load by a PCR-based assay. c) Renal: Creatinine clearance (calculated creatinine clearance is permitted) > 40 mL/min. d) Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), or forced vital capacity (FVC) ? 45% of predicted (corrected for hemoglobin).
Decrease in FEV1 of >= 12% from the baseline (FEV1/forced vital capacity [FVC] ratio < 0.8); NOTE: baseline may be defined as either pre- or post-transplant, as assessed by the treating physician
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 50% of predicted (for patients who have not received thoracic or mantle irradiation; for patients who have received thoracic or mantle irradiation, FEV1 and FVC >= 70% of predicted
Pulmonary function tests (PFT)-forced expiratory volume in one second (FEV1), diffusing capacity of the lung for carbon monoxide (DLCO2), and forced vital capacity (FVC) >= 60% predicted value if clinically indicated
Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) or diffusion capacity of carbon monoxide (DLCO) > 50% predicted- before admission for transplant as per institutional standards; patients on home oxygen are not allowed on the protocol
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and adjusted diffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of predicted values on pulmonary function tests
Adequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) at least 45% of expected corrected for hemoglobin; children unable to perform pulmonary functions must have an oxygen saturation greater than 92% at room air
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and corrected diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% predicted
Pulmonary: Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and carbon monoxide diffusing capacity (DLCO) (corrected for Hb) greater than 50% predicted; for patients in which pulse oxymetry is performed, O2 saturation greater than 92%
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) > 60% predicted by pulmonary function test; for children who are unable to do pulmonary function tests (PFTs), no evidence of dyspnea at rest and no exercise intolerance should be documented; note: the pulmonary function test must be performed within 4 weeks prior to enrollment
Forced expiratory volume (FEV)1, forced vital capacity (FVC) and carbon monoxide diffusing capability (DLCO) (corrected for hemoglobin [Hgb]) >= 50%
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 40% predicted, corrected diffusion capacity of the lung for carbon monoxide (DLCOc) >= 40% predicted
Subjects with evidence of underlying obstructive pulmonary disease prior to transplant (clinical history of asthma or baseline forced expiratory volume in 1 second [FEV1] < 80% predicted with FEV1/forced vital capacity [FVC] < 80%)
Pulmonary disease with forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) or diffusion capacity of the lung for carbon monoxide (DLCO) parameters < 45% predicted (corrected for hemoglobin) or requiring supplemental oxygen; children who are developmentally unable to perform pulmonary function testing will be assessed solely on their need for supplemental oxygen
Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin), forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 50% predicted
Forced vital capacity (FVC) or forced expiratory volume of the lung in 1 second (FEV1) >= 40% predicted
Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? 50% (adjusted for hemoglobin), and forced expiratory volume in one second (FEV1) or forced vital capacity (FVC) ? 50%; for children who are unable to perform for Pulmonary Function Tests (PFTs) due to age or developmental ability, there must be no evidence of dyspnea and no need for supplemental oxygen, as evidenced by O2 saturation ? 92% on room air.
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and adjusted diffusion capacity of the lung for carbon monoxide (DLCO) must be >= 50% of predicted values
Forced expiratory volume 1 (FEV1), forced vital capacity (FVC), and adjusted diffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of predicted values on pulmonary function tests
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusion capacity of the lung for carbon monoxide (DLCO) adjusted >= 50% of predicted values on pulmonary function tests
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted values on pulmonary function tests
Diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) >= 40% predicted, and absence of oxygen (O2) requirements
Patients must have adequate pulmonary function: forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) at least 60% predicted value by spirometry
Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 50% predicted, corrected carbon monoxide diffusing capability test (DLCO) >= 40% predicted
At least one of the following:\r\n* Mild or worse sputum cytologic atypia\r\n* Endobronchial dysplasia (score >= 4) on a previous bronchoscopy.\r\n* At least mild airflow limitation on pulmonary function testing (forced expiratory volume in one second [FEV1]/forced vital capacity [FVC] < 70% actual)
COPD, defined as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 70% and FEV1% predicted < 80%
Forced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
Patients must have postoperative predicted forced expiratory volume (FEV) > 35% prior to surgery obtained within 28 days prior to step 2 registration
Pulmonary function forced expiratory volume in 1 second (FEV1) >= 50% of predicted
Chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) is less than (<) 50 % of predicted normal
Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal\r\n* Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal
Participants with unilateral pleural effusion are eligible if they fulfill both of the following: (a) New York Heart Association (NYHA) Class 1; (b) Global initiative for obstructive lung disease (GOLD) test level 1 (forced expiratory volume in 1 second [FEV1]/ forced vital capacity [FVC] less than [<] 0.7 and FEV1 greater than or equal to [>=] 80 percent [%] predicted after inhaled bronchodilator)
PFTs including forced expiratory volume in 1 second (FEV1) within 26 weeks prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 0.8 liters/second or >= 50% predicted
All patients must have an forced expiratory volume in 1 second (FEV1) >= 700cc
Forced expiratory volume in 1 second (FEV1) > 65% of prediction for those patients with extensive pulmonary metastases or chronic pulmonary disease history
Documented forced expiratory volume in 1 second (FEV1) of less than or equal to 50% predicted in patients with clinical symptomatology
Uncontrolled asthma (defined as having 3 or more of the following features of partially controlled asthma within 28 days prior to starting study treatment: Daytime symptoms more than twice per week, any limitation of activities, any nocturnal symptoms/awaking, need for reliever/rescue inhaler more than twice per week, or known lung function [peak expiratory flow (PEF) or forced expiratory volume in 1 second (FEV1)] without administration of a bronchodilator that is < 80% predicted or personal best [if known]).
Known severe chronic obstructive pulmonary disease or asthma defined as forced expiratory volume (FEV1) in 1 second less than < 60% of expected
Patients who have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of ? 60%
Severe obstructive airway disease defined by forced expiratory volume at one second (FEV1) < 50%
Forced expiratory volume in 1 second (FEV1) > 1.0 L
Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. NOTE: FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal
Patients with unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class 3 or 4) or lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitus
Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal.
Uncontrolled asthma (defined as having 3 or more of the following features of partially controlled asthma within 28 days prior to starting study treatment: daytime symptoms more than twice per week, any limitation of activities, any nocturnal symptoms/awaking, need for reliever/rescue inhaler more than twice per week, or known lung function [peak expiratory flow (PEF) or forced expiratory volume in 1 second (FEV1)] without administration of a bronchodilator that is < 80% predicted or personal best [if known])
Forced expiratory volume in 1 second (FEV1) >= 30% of predicted postoperative (ppoFEV1, as if patient underwent a pneumonectomy)
Adequate cardiopulmonary reserve defined as follows as assessed within 4 months of study entry:\r\n* Predicted postoperative forced expiratory volume FEV1 > 1L\r\n* Normal left ventricular function (ejection fraction EF ? 45%) and right ventricular function\r\n* No pulmonary hypertension noted on preoperative transthoracic echocardiography
Pre-treatment pulmonary function tests (PFTs), collected =< 90 days prior to enrollment, must show forced expiratory volume in one second (FEV1) > 60% of predicted
Diffusing capacity divided by the alveolar volume (DDLCO/VA) and forced expiratory volume (FEV) – 1.0 > 50% of predicted on pulmonary function tests
Forced expiratory volume in 1 second (FEV1) > 50%
Forced expiratory volume in 1 second (FEV1) >= 50%
Unstable or severe intercurrent medical conditions such as severe heart (New York Association class 3 or 4) or lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitus
Forced expiratory volume in 1 second (FEV1) >= 50% of expected corrected for hemoglobin and/or volume
Forced expiratory volume in one second (FEV1) < 50% (corrected for hemoglobin)
FEV1 (forced expiratory volume in 1 second) >= 50% predicted
Forced expiratory volume in 1 second (FEV1) > 65%
Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with a forced expiratory volume in one second (FEV1) of < 50 % of predicted will be excluded
Forced expiratory volume in one second (FEV1) >= 50% of expected, corrected for hemoglobin
Forced expiratory volume in 1 second (FEV1) > 65% of predicted within 6 months of lymphodepletion (Turnstile II) or
Forced expiratory volume in one second (FEV1) >= 50%
Forced expiratory volume in one second (FEV1) >= 50%
Adequate lung function indicated by forced expiratory volume at 1 second (FEV1) >= 1 L is required
For patients enrolled post-P/D, only: forced expiratory volume in 1 second (FEV1) >= 35% (corrected for Hgb) (Note: patients enrolled prior to P/D will have pulmonary function tests (PFTs) repeated pre-IMRT; if this criteria is not met, they will be removed from study)
Forced expiratory volume in one second (FEV1) 40% of predicted or 3 standard deviations (SD) below normal
Forced expiratory volume in one second (FEV1) >= 50% of expected value obtained within 90 days of enrollment\r\n* Note: For children who are unable to cooperate for positron emission tomography (PFT)s, the criterion is: No evidence of dyspnea at rest, no exercise intolerance, and no requirement for supplemental oxygen therapy
Forced expiratory volume in one second (FEV1) >= 50%
FEV1 (forced expiratory volume in the first second) >= 50% of predicted, corrected for volume and hemoglobin
Forced expiratory volume in 1 second (FEV1) > 60% by pulmonary function test
With known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note: FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is <50% of predicted normal.
Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% predicted normal; Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV < 50%
Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. NOTE: FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal
Pulmonary disease: forced expiratory volume in 1 second (FEV1) < 60% predicted
> 50% forced expiratory volume of the lung in 1 second (FEV1), if presence of pleural effusion due to metastatic disease > 40% corrected FEV1 is acceptable (within 28 days of treatment start)
Forced expiratory volume >= 1.0 L or >= 40% of predicted with or without bronchodilators by pulmonary function testing
Forced expiratory volume in 1 second (FEV1) >= 50% of predicted value
Forced expiratory volume in one second (FEV1) >= 50% predicted
Forced expiratory volume in one second (FEV1) >= 50% of predicted value (corrected to serum hemoglobin)
Adequate pulmonary function based on the following pulmonary function tests done within 8 weeks of registration:\r\n* Forced expiratory volume (FEV)1 at least 2.0 liters; if less than 2.0 liters, the predicted post-resection FEV1 must be at least 0.8 liters \r\n* Diffusion capacity should be >= 50% predicted
Forced expiratory volume in 1 second (FEV1) < 50% of normal
Known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) less than (<)50 percent (%) of predicted normal
Has chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted normal
Patients must have pulmonary function tests (PFTs) including forced expiratory volume in 1 second (FEV1) within 84 days prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 1.2 liters/second and/or >= 50% predicted
Forced expiratory volume in one second (FEV1) with >= 1200 cc or >= 50% predicted
Forced expiratory volume of the lung in 1 second (FEV1) >= 40% predicted
Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal or known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification
Patients who would be receiving SBRT for lung tumors who are known or suspected by the treating radiation oncologist to have compromised lung function must have a documented forced expiratory volume in 1 second (FEV1) >= 1 L
Forced expiratory volume in one second (FEV-1) >= 50%
Has known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal (note that FEV1 testing is required for subjects suspected of having chronic obstructive pulmonary disease and subjects must be excluded if FEV1 < 50% of predicted normal)
Forced expiratory volume in 1 second (FEV1) >= 50%
Forced expiratory volume in 1 second (FEV1) >= 50%
Forced expiratory volume in one second (FEV1) testing required only if symptomatic or prior known impairment
Forced expiratory volume in 1 second (FEV1) >= 1 liter
Forced expiratory volume in 1 second (FEV1) >= 2.0 liters or >= 75% of predicted for height and age; (pulmonary function tests [PFTs] are required for patients over 50 or with significant pulmonary or smoking history)
Patients be able to undergo VATS resection as defined below:\r\n* Preoperative forced expiratory volume in 1 second (FEV1) >= 40% predicted OR\r\n* Post-operative predicted FEV1 >= 0.8 l\r\n* Mercury (Hg) >= 8.0\r\n* No evidence of coronary ischemia on cardiac evaluation per institutional standard (ie. cardiology evaluation, stress test, etc.)
Forced expiratory volume in one second (FEV1) must be >= 1.0 L
Forced expiratory volume (FEV) < 30% predicted
Forced expiratory volume in 1 second (FEV1) > 2.0 liters or > 75% of predicted for height and age; pulmonary function tests (PFTs) are required for patients over 50 years old or with significant pulmonary or smoking history
Forced expiratory volume (FEV) =< 1.2 L/s
Forced expiratory volume of the lung in one second (FEV1) > 40% of predicted at the screening visit
Forced expiratory volume in one second (FEV1) >= 50% of expected corrected for hemoglobin
Current severely impaired lung function (i.e., forced expiratory volume in 1 second [FEV1] < 1 liter)
Forced expiratory volume in 1 second (FEV1) >= 40% of predicted
Forced expiratory volume (FEV) 1 > 2.0 liters or > 75% of predicted for height and age (pulmonary function test [PFTs] are required for patients over 50 years old or with significant pulmonary or smoking history)
Forced expiratory volume in one second (FEV1) >= 40%; no symptomatic pulmonary disease
History of severe chronic obstructive pulmonary disease (COPD) defined as a forced expiratory volume in 1 second (FEV1) < 50% of predicted
Advanced pulmonary disease as assessed by clinical symptoms of shortness of breath or known forced expiratory volume in 1 second (FEV1) < 1
Patients with severe chronic obstructive pulmonary disease (COPD) defined as a forced expiratory volume in one second (FEV1) < 50%
Severe obstructive lung disease (forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] < 70% post bronchodilator and forced expiratory volume in 1 second < 30% predicted)
FEV1 (forced expiratory volume in 1 second) >= 50% predicted
A forced expiratory volume in one second (FEV1) of 60% or greater, a diffusion capacity of 50% or greater, and a oxygen partial pressure (PO2) of 80 mm mercury (Hg) or greater on pulmonary function testing
Forced expiratory volume in 1 second (FEV1) > 800 cc
Chronic obstructive pulmonary disease (COPD), Global Initiative for Chronic Obstructive Lung Disease (GOLD) II or greater (defined as forced expiratory volume in 1 second [FEV1]/ forced vital capacity [FVC] < 70% and FEV1 % predicted < 80%)
Forced expiratory volume at one second (FEV1): best value obtained pre- or post-bronchodilator must be ? 1.0 liters/second or > 50% predicted value
Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% predicted normal; Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50%